Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy

Marta Boffito, Edward Acosta, David Burger, Courtney V Fletcher, Charles Flexner, Rodolphe Garaffo, Giorgio Gatti, Michael Kurowski, Carlo Federico Perno, Gilles Peytavin, Mario Regazzi, David Back

Research output: Contribution to journalReview article

61 Citations (Scopus)

Abstract

The consensus of current international guidelines for the treatment of HIV infection is that data on therapeutic drug monitoring (TDM) of non-nucleoside reverse transcriptase inhibitors and protease inhibitors provide a framework for the implementation of TDM in certain defined scenarios in clinical practice. However, the utility of TDM is considered to be on an individual basis until more data are obtained from large clinical trials showing the benefit of TDM. In April 2004, a panel of experts met in Rome, Italy. This followed an inaugural meeting in Perugia, Italy, in October 2000, which resulted in the article published in AIDS 2002, 16(Suppl 1):S5-S37. The objectives of this second meeting were to review the questions surrounding TDM of antiretroviral drugs and discuss the clinical utility, current concerns and future prospects of drug concentration monitoring in the care of HIV-1-infected individuals. This report, which has been updated to include material published or presented at international conferences up to the end of September 2004, reviews pharmacokinetic and pharmacodynamic data and reports the issues discussed by the panel, offering advice to clinical care providers who may be currently, or are considering incorporating TDM into the routine care of their patients. In addition, the panel formulated a series of position statements that are relevant to the interpretation of current data and can aid the design of future clinical trials.

Original languageEnglish (US)
Pages (from-to)375-392
Number of pages18
JournalAntiviral Therapy
Volume10
Issue number3
StatePublished - Aug 25 2005

Fingerprint

Clinical Pharmacology
Drug Monitoring
Italy
Therapeutics
Clinical Trials
Reverse Transcriptase Inhibitors
Protease Inhibitors
HIV Infections
HIV-1
Patient Care
Acquired Immunodeficiency Syndrome
Pharmacokinetics
Guidelines
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy. / Boffito, Marta; Acosta, Edward; Burger, David; Fletcher, Courtney V; Flexner, Charles; Garaffo, Rodolphe; Gatti, Giorgio; Kurowski, Michael; Perno, Carlo Federico; Peytavin, Gilles; Regazzi, Mario; Back, David.

In: Antiviral Therapy, Vol. 10, No. 3, 25.08.2005, p. 375-392.

Research output: Contribution to journalReview article

Boffito, M, Acosta, E, Burger, D, Fletcher, CV, Flexner, C, Garaffo, R, Gatti, G, Kurowski, M, Perno, CF, Peytavin, G, Regazzi, M & Back, D 2005, 'Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy', Antiviral Therapy, vol. 10, no. 3, pp. 375-392.
Boffito, Marta ; Acosta, Edward ; Burger, David ; Fletcher, Courtney V ; Flexner, Charles ; Garaffo, Rodolphe ; Gatti, Giorgio ; Kurowski, Michael ; Perno, Carlo Federico ; Peytavin, Gilles ; Regazzi, Mario ; Back, David. / Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy. In: Antiviral Therapy. 2005 ; Vol. 10, No. 3. pp. 375-392.
@article{1a71f4d853634b67b4425a5715c61900,
title = "Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy",
abstract = "The consensus of current international guidelines for the treatment of HIV infection is that data on therapeutic drug monitoring (TDM) of non-nucleoside reverse transcriptase inhibitors and protease inhibitors provide a framework for the implementation of TDM in certain defined scenarios in clinical practice. However, the utility of TDM is considered to be on an individual basis until more data are obtained from large clinical trials showing the benefit of TDM. In April 2004, a panel of experts met in Rome, Italy. This followed an inaugural meeting in Perugia, Italy, in October 2000, which resulted in the article published in AIDS 2002, 16(Suppl 1):S5-S37. The objectives of this second meeting were to review the questions surrounding TDM of antiretroviral drugs and discuss the clinical utility, current concerns and future prospects of drug concentration monitoring in the care of HIV-1-infected individuals. This report, which has been updated to include material published or presented at international conferences up to the end of September 2004, reviews pharmacokinetic and pharmacodynamic data and reports the issues discussed by the panel, offering advice to clinical care providers who may be currently, or are considering incorporating TDM into the routine care of their patients. In addition, the panel formulated a series of position statements that are relevant to the interpretation of current data and can aid the design of future clinical trials.",
author = "Marta Boffito and Edward Acosta and David Burger and Fletcher, {Courtney V} and Charles Flexner and Rodolphe Garaffo and Giorgio Gatti and Michael Kurowski and Perno, {Carlo Federico} and Gilles Peytavin and Mario Regazzi and David Back",
year = "2005",
month = "8",
day = "25",
language = "English (US)",
volume = "10",
pages = "375--392",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "3",

}

TY - JOUR

T1 - Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy

AU - Boffito, Marta

AU - Acosta, Edward

AU - Burger, David

AU - Fletcher, Courtney V

AU - Flexner, Charles

AU - Garaffo, Rodolphe

AU - Gatti, Giorgio

AU - Kurowski, Michael

AU - Perno, Carlo Federico

AU - Peytavin, Gilles

AU - Regazzi, Mario

AU - Back, David

PY - 2005/8/25

Y1 - 2005/8/25

N2 - The consensus of current international guidelines for the treatment of HIV infection is that data on therapeutic drug monitoring (TDM) of non-nucleoside reverse transcriptase inhibitors and protease inhibitors provide a framework for the implementation of TDM in certain defined scenarios in clinical practice. However, the utility of TDM is considered to be on an individual basis until more data are obtained from large clinical trials showing the benefit of TDM. In April 2004, a panel of experts met in Rome, Italy. This followed an inaugural meeting in Perugia, Italy, in October 2000, which resulted in the article published in AIDS 2002, 16(Suppl 1):S5-S37. The objectives of this second meeting were to review the questions surrounding TDM of antiretroviral drugs and discuss the clinical utility, current concerns and future prospects of drug concentration monitoring in the care of HIV-1-infected individuals. This report, which has been updated to include material published or presented at international conferences up to the end of September 2004, reviews pharmacokinetic and pharmacodynamic data and reports the issues discussed by the panel, offering advice to clinical care providers who may be currently, or are considering incorporating TDM into the routine care of their patients. In addition, the panel formulated a series of position statements that are relevant to the interpretation of current data and can aid the design of future clinical trials.

AB - The consensus of current international guidelines for the treatment of HIV infection is that data on therapeutic drug monitoring (TDM) of non-nucleoside reverse transcriptase inhibitors and protease inhibitors provide a framework for the implementation of TDM in certain defined scenarios in clinical practice. However, the utility of TDM is considered to be on an individual basis until more data are obtained from large clinical trials showing the benefit of TDM. In April 2004, a panel of experts met in Rome, Italy. This followed an inaugural meeting in Perugia, Italy, in October 2000, which resulted in the article published in AIDS 2002, 16(Suppl 1):S5-S37. The objectives of this second meeting were to review the questions surrounding TDM of antiretroviral drugs and discuss the clinical utility, current concerns and future prospects of drug concentration monitoring in the care of HIV-1-infected individuals. This report, which has been updated to include material published or presented at international conferences up to the end of September 2004, reviews pharmacokinetic and pharmacodynamic data and reports the issues discussed by the panel, offering advice to clinical care providers who may be currently, or are considering incorporating TDM into the routine care of their patients. In addition, the panel formulated a series of position statements that are relevant to the interpretation of current data and can aid the design of future clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=20444506418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444506418&partnerID=8YFLogxK

M3 - Review article

VL - 10

SP - 375

EP - 392

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 3

ER -